The pharmacotherapy for pediatric obesity: insights and challenges from adult weight-loss medications.
There is a pressing need for pediatric clinical trials to evaluate the safety and efficacy of weight-loss medications like semaglutide, given the challenges faced in treating childhood obesity.
Where it sits
this study against the rest of the semaglutide corpusSummary and findings
This review discusses the challenges and insights regarding pharmacotherapy for pediatric obesity, particularly focusing on GLP-1 receptor agonists like semaglutide. It emphasizes the need for pediatric clinical trials to verify the safety and efficacy of these medications. The paper highlights the historical context of weight-loss drugs and the current landscape of treatment options for adolescents.
Abstract
Obesity significantly increases the risk of developing other chronic diseases and shortens the life expectancy by 5 to 8 years. Childhood obesity is particularly prominent as 80% of teenagers with obesity have shown it to persist into adulthood. With reference to the development of adult medication, the present review summarises the recent research progress in the development of pediatric anti-obesity drugs. The current management guidelines support the use of medication for adolescents aged 12 and above when lifestyle measures are ineffective. Early weight-loss drugs like the serotonergic agonist fenfluramine and the norepinephrine reuptake inhibitor sibutramine were withdrawn due to severe safety issues. Rainbow pills and the CB<sub>1</sub> inhibitor rimonabant also failed over neuropsychiatric toxicity. These highlighted inadequate safety profiling in initial development, and there were almost no studies on children. Recently, GLP-1 receptor agonists, such as semaglutide, and the dual-target agonist tirzepatide have gained popularity among adults and adolescents with obesity. However, it still faces significant limitations, including the long-term neurodevelopmental safety of adolescents, high costs and limited insurance coverage, and widespread gastrointestinal side effects. It is foreseeable that the focus of adult weight loss medication research may gradually shift to multi-target new drugs, including the dual agonist mazdutide and the triple receptor agonist retatrutide. Therefore, the development of pediatric weight loss drugs should also focus on the GLP-1 receptor agonists and multi-target new drugs. In addition, there is an urgent need to verify the safety and efficacy of approved weight loss medications through pediatric clinical trials.<h4>Graphical abstract</h4>
Background
This review addresses the clinical question of how pharmacotherapy can be effectively utilized in treating pediatric obesity, a condition that has significant long-term health implications. Previous research has shown that childhood obesity often persists into adulthood, increasing the risk of chronic diseases. The study is important as it summarizes recent advancements and challenges in developing anti-obesity medications for children, particularly in light of past failures of weight-loss drugs.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
The review suggests that while GLP-1 receptor agonists like semaglutide are gaining traction, there are still concerns regarding their long-term safety in adolescents. The findings indicate that despite some medications showing promise, the effect sizes and safety profiles need thorough evaluation in pediatric populations. The review also points out that many previous weight-loss medications have failed due to safety issues, which raises caution about the current options.
Key findings
- Obesity shortens life expectancy by 5 to 8 years.
- 80% of teenagers with obesity have shown it to persist into adulthood.
- Early weight-loss drugs like fenfluramine and sibutramine were withdrawn due to severe safety issues.
- GLP-1 receptor agonists, such as semaglutide, have gained popularity among adults and adolescents with obesity.
Limitations
- Not enough studies on children regarding safety and efficacy.
- Past weight-loss drugs have been withdrawn due to severe safety issues.
- High costs and limited insurance coverage for current medications.
- Widespread gastrointestinal side effects reported.